🚨 Breaking News in Hemophilia B Treatment 🚨
Pfizer has announced it will discontinue its hemophilia B gene therapy, Beqvez (fidanacogene elaparvovec), citing limited demand. Approved just last year, this $3.5M therapy showed promising results but hasn't seen the expected uptake. 📉
Instead, Pfizer will shift focus to their other treatments like Hympavzi (marstacimab), a new hope for both hemophilia A & B patients, promoting better clotting without needing factor treatments. 💉🧬
For those wondering about alternatives, Hemgenix remains an approved gene therapy option for hemophilia B. 💊
Stay informed and connected for more updates! #HemophiliaB #GeneTherapy #HealthcareNews #hemophilia
In a recent announcement, Pfizer made headlines by discontinuing its hemophilia B gene therapy, Beqvez (fidanacogene elaparvovec), due to lower-than-expected demand since its approval last year at a price tag of $3.5 million. While the therapy had shown promise in clinical trials, patient uptake fell short, leading to this significant shift in strategy. As Pfizer pivots towards Hympavzi (marstacimab), it emphasizes the potential of this treatment for both hemophilia A and B patients, aimed at improving clotting without the need for traditional factor treatments. This offers new hope for individuals living with these conditions, simplifying their treatment journey. For those seeking alternative gene therapies, Hemgenix remains a viable and approved option for hemophilia B patients, providing an additional avenue for effective management of this genetic disorder. As changes unfold in the hemophilia treatment landscape, staying informed on available therapies and ongoing developments is essential for patients and healthcare professionals alike.